首页> 外文期刊>Nucleic Acids Research >Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations
【24h】

Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations

机译:无选择基因修复在设计者核酸血管核酸患者中的转导后:DMD肌肉细胞群中的营养不良酶合成

获取原文
获取原文并翻译 | 示例
           

摘要

Duchenne muscular dystrophy (DMD) is a fatal X-linked muscle-wasting disorder caused by mutations in the 2.4 Mb dystrophin-encoding DMD gene. The integration of gene delivery and gene editing technologies based on viral vectors and sequence-specific designer nucleases, respectively, constitutes a potential therapeutic modality for permanently repairing defective DMD alleles in patient-derived myogenic cells. Therefore, we sought to investigate the feasibility of combining adenoviral vectors (AdVs) with CRISPR/Cas9 RNA-guided nucleases (RGNs) alone or together with transcriptional activator-like effector nucleases (TALENs), for endogenous DMD repair through non-homologous end-joining (NHEJ). The strategies tested involved; incorporating small insertions or deletions at out-of-frame sequences for reading frame resetting, splice acceptor knockout for DNA-level exon skipping, and RGN-RGN or RGN-TALEN multiplexing for targeted exon(s) removal. We demonstrate that genome editing based on the activation and recruitment of the NHEJ DNA repair pathway after AdV delivery of designer nuclease genes, is a versatile and robust approach for repairing DMD mutations in bulk populations of patient-derived muscle progenitor cells (up to 37% of corrected DMD templates). These results open up a DNA-level genetic medicine strategy in which viral vector-mediated transient designer nuclease expression leads to permanent and regulated dystrophin synthesis from corrected native DMD alleles.
机译:杜兴肌营养不良(DMD)是由在2.4 MB肌营养不良蛋白编码DMD基因中的突变致命X连锁肌肉萎缩疾病。基因递送和基于病毒载体和序列特异性核酸酶的设计者基因编辑技术的集成,分别构成了用于在患者来源的肌原细胞永久修复缺陷的DMD等位基因的潜在治疗模态。因此,我们寻求研究结合起来CRISPR / Cas9 RNA引导的核酸酶(RGNs)腺病毒载体(ADVS)的可行性单独或连同转录激活样效应核酸酶(TALEN的),内源性修复DMD通过非同源最终连接(NHEJ)。该战略涉及的测试;掺入小插入或缺失在框外序列用于读取帧复位,剪接受体敲除对DNA级外显子跳跃,和RGN-RGN或RGN-TALEN复用靶向外显子(一个或多个)的去除。我们表明,基因组基于使用ADV交付的设计师核酸酶基因后的NHEJ DNA修复途径的激活和招聘编辑,是一种多用途和可靠的方法对来自患者的肌肉祖细胞的散装群体修复DMD基因突变(高达37%修正的DMD模板)。这些结果开辟DNA级遗传药策略,其中病毒载体介导的瞬时设计师核酸酶表达导致永久的和调节的肌营养不良蛋白合成从校正天然DMD等位基因。

著录项

  • 来源
    《Nucleic Acids Research》 |2016年第3期|共22页
  • 作者单位

    Leiden Univ Med Ctr Dept Mol Cell Biol Einthovenweg 20 NL-2333 ZC Leiden Netherlands;

    Leiden Univ Med Ctr Dept Mol Cell Biol Einthovenweg 20 NL-2333 ZC Leiden Netherlands;

    Leiden Univ Med Ctr Dept Mol Cell Biol Einthovenweg 20 NL-2333 ZC Leiden Netherlands;

    Leiden Univ Med Ctr Dept Mol Cell Biol Einthovenweg 20 NL-2333 ZC Leiden Netherlands;

    Leiden Univ Med Ctr Dept Mol Cell Biol Einthovenweg 20 NL-2333 ZC Leiden Netherlands;

    FRE 3617 CNRS Ctr Res Myol UMRS UPMC INSERM 974 Paris France;

    Leiden Univ Med Ctr Dept Mol Cell Biol Einthovenweg 20 NL-2333 ZC Leiden Netherlands;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号